AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
Pharmacodynamic model of topotecan-induced time course of neutropenia
Authors: Zamboni, WC D'Argenio, DZ Stewart, CF MacVittie, T Delauter, BJ Farese, AM Potter, DM Kubat, NM Tubergen, D Egorin, MJ
Citation: Wc. Zamboni et al., Pharmacodynamic model of topotecan-induced time course of neutropenia, CLIN CANC R, 7(8), 2001, pp. 2301-2308
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid
Authors: Zamboni, WC Luftner, DI Egorin, MJ Schweigert, M Sezer, O Richter, T Natale, JJ Possinger, K
Citation: Wc. Zamboni et al., The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid, ANN ONCOL, 12(1), 2001, pp. 119-122
Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma ofthe head and neck
Authors: Rosenthal, DI Lee, JH Sinard, R Yardley, DA Machtay, M Rosen, DM Egorin, MJ Weber, RS Weinstein, GS Chalian, AA Miller, LK Frenkel, EP Carbone, DP
Citation: Di. Rosenthal et al., Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma ofthe head and neck, J CL ONCOL, 19(5), 2001, pp. 1363-1373
In regard to Suntharalingamet al. - Response
Authors: Suntharalingam, M Haas, ML Herman, JM Conley, BA Egorin, MJ Levy, S Sivasailam, S Van Echo, DA Gray, WC Ord, RA Aisner, JA
Citation: M. Suntharalingam et al., In regard to Suntharalingamet al. - Response, INT J RAD O, 49(1), 2001, pp. 281-282
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats
Authors: Stecklair, KP Hamburger, DR Egorin, MJ Parise, RA Covey, JM Eiseman, JL
Citation: Kp. Stecklair et al., Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats, CANC CHEMOT, 48(5), 2001, pp. 375-382
Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates
Authors: Kerr, JZ Berg, SL Dauser, R Nuchtern, J Egorin, MJ McGuffey, A Aleksic, A Blaney, S
Citation: Jz. Kerr et al., Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates, CANC CHEMOT, 47(5), 2001, pp. 411-414
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1
Authors: Egorin, MJ Zuhowski, EG Rosen, DM Sentz, DL Covey, JM Eiseman, JL
Citation: Mj. Egorin et al., Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1, CANC CHEMOT, 47(4), 2001, pp. 291-302
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer
Authors: Papadopoulos, KP Egorin, MJ Huang, M Troxel, AB Kaufman, E Balmaceda, CM Vahdat, LT Hesdorffer, CS
Citation: Kp. Papadopoulos et al., The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer, CANC CHEMOT, 47(1), 2001, pp. 45-50
Adenosine triphosphate-binding cassette proteins and bioavailability: "We can pump you up (or out)"
Authors: Egorin, MJ
Citation: Mj. Egorin, Adenosine triphosphate-binding cassette proteins and bioavailability: "We can pump you up (or out)", J NAT CANC, 92(20), 2000, pp. 1628-1629
Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies
Authors: Murren, JR DiStasio, SA Lorico, A McKeon, A Zuhowski, EG Egorin, MJ Sartorelli, AC Rappa, G
Citation: Jr. Murren et al., Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies, CANCER J, 6(4), 2000, pp. 256-265
Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma
Authors: Parise, RA Miles, DR Egorin, MJ
Citation: Ra. Parise et al., Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma, J CHROMAT B, 749(2), 2000, pp. 145-152
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity
Authors: Muldoon, LL Pagel, MA Kroll, RA Brummett, RE Doolittle, ND Zuhowski, EG Egorin, MJ Neuwelt, EA
Citation: Ll. Muldoon et al., Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity, CLIN CANC R, 6(1), 2000, pp. 309-315
Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion
Authors: Ain, KB Egorin, MJ DeSimone, PA
Citation: Kb. Ain et al., Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion, THYROID, 10(7), 2000, pp. 587-594
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies
Authors: Fracasso, PM Westerveldt, P Fears, CA Rosen, DM Zuhowski, EG Cazenave, LA Litchman, M Egorin, MJ
Citation: Pm. Fracasso et al., Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies, J CL ONCOL, 18(5), 2000, pp. 1124-1134
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
Authors: Patnaik, A Warner, E Michael, M Egorin, MJ Moore, MJ Siu, LL Fracasso, PM Rivkin, S Kerr, I Litchman, M Oza, AM
Citation: A. Patnaik et al., Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors, J CL ONCOL, 18(21), 2000, pp. 3677-3689
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors
Authors: Zamboni, WC Egorin, MJ Van Echo, DA Day, RS Meisenberg, BR Brooks, SE Doyle, LA Nemieboka, NN Dobson, JM Tait, NS Tkaczuk, KH
Citation: Wc. Zamboni et al., Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors, J CL ONCOL, 18(18), 2000, pp. 3288-3294
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565
Authors: Venook, AP Egorin, MJ Rosner, GL Hollis, D Mani, S Hawkins, M Byrd, J Hohl, R Budman, D Meropol, NJ Ratain, MJ
Citation: Ap. Venook et al., Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565, J CL ONCOL, 18(14), 2000, pp. 2780-2787
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck
Authors: Suntharalingam, M Haas, ML Conley, BA Egorin, MJ Levy, S Sivasailam, S Herman, JM Jacobs, MC Gray, WC Ord, RA Aisner, JA Van Echo, DA
Citation: M. Suntharalingam et al., The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck, INT J RAD O, 47(1), 2000, pp. 49-56
Phase I study of docetaxel and topotecan in patients with solid tumors
Authors: Tkaczuk, KH Zamboni, WC Tait, NS Meisenberg, BR Doyle, LA Edelman, MJ Hausner, PF Egorin, MJ Van Echo, DA
Citation: Kh. Tkaczuk et al., Phase I study of docetaxel and topotecan in patients with solid tumors, CANC CHEMOT, 46(6), 2000, pp. 442-448
Pharmacokinetics of gemcitabine and 2 ',2 '-difluorodeoxyuridine in a patient with ascites
Authors: Delauter, BJ Ramanathan, RK Egorin, MJ Stover, LL Zuhowski, EG Plunkett, W Zamboni, WC
Citation: Bj. Delauter et al., Pharmacokinetics of gemcitabine and 2 ',2 '-difluorodeoxyuridine in a patient with ascites, PHARMACOTHE, 20(10), 2000, pp. 1204-1207
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
Authors: Sparano, JA Speyer, J Gradishar, WJ Liebes, L Sridhara, R Mendoza, S Fry, D Egorin, MJ
Citation: Ja. Sparano et al., Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer, J CL ONCOL, 17(3), 1999, pp. 880-886
Phase I trial, including pharmacokinetic and pharmacodynamic correlations,of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
Authors: Belani, CP Kearns, CM Zuhowski, EG Erkmen, K Hiponia, D Zacharski, D Engstrom, C Ramanathan, RK Capozzoli, MJ Aisner, J Egorin, MJ
Citation: Cp. Belani et al., Phase I trial, including pharmacokinetic and pharmacodynamic correlations,of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer, J CL ONCOL, 17(2), 1999, pp. 676-684
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 [NSC 676418], a silicone phthalocyanine photodynamic sensitizing agent
Authors: Egorin, MJ Zuhowski, EG Sentz, DL Dobson, JM Callery, PS Eiseman, JL
Citation: Mj. Egorin et al., Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 [NSC 676418], a silicone phthalocyanine photodynamic sensitizing agent, CANC CHEMOT, 44(4), 1999, pp. 283-294
A pilot phase I trial of continuous hyperthermic peritoneal perfusion withhigh-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer (vol 43, pg 106, 1999)
Authors: Steller, MA Egorin, MJ Trimble, EL Bartlett, DL Zuhowski, EG Alexander, HR Dedrick, RL
Citation: Ma. Steller et al., A pilot phase I trial of continuous hyperthermic peritoneal perfusion withhigh-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer (vol 43, pg 106, 1999), CANC CHEMOT, 44(1), 1999, pp. 90-90
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats
Authors: Egorin, MJ Yuan, ZM Sentz, DL Plaisance, K Eiseman, JL
Citation: Mj. Egorin et al., Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats, CANC CHEMOT, 43(6), 1999, pp. 445-453
Risultati: 1-25 | 26-27